ArticleDiscover oncology2026

Crizotinib or vebreltinib response and resistance in advanced non-small cell lung cancer with MET exon 14 skipping.

Jiao Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.